Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
Depemokimab reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype. (Funded by GSK; SWIFT-1 and SWIFT-2 ClinicalTrials.gov numbers, NCT04719832 and NCT04718103.).
Authors
- Gustavo de Luíz Martinez
- Daniel J. Jackson (ORCID: https://orcid.org/0000-0001-6938-2690)
- Douglas G. Smith (ORCID: https://orcid.org/0000-0002-6207-7711)
- Michael E. Wechsler (ORCID: https://orcid.org/0000-0003-3505-2946)
- Loretta Jacques (ORCID: https://orcid.org/0000-0001-7293-3246)
- Lucyna Dymek
- Paul Pfeffer
- Stephanie Korn (ORCID: https://orcid.org/0009-0001-2239-5029)
- Ruchong Chen (ORCID: https://orcid.org/0000-0001-5376-8230)
- Nicholas Bird
- Stein Schalkwijk (ORCID: https://orcid.org/0000-0001-8204-5242)
- David J. Jackson (ORCID: https://orcid.org/0000-0002-2299-868X)
- Ian Pavord (ORCID: https://orcid.org/0000-0002-4288-5973)
- Peter Howarth (ORCID: https://orcid.org/0000-0003-0619-7927)
- Junpei Saito (ORCID: https://orcid.org/0000-0002-9876-1160)
- David I. Bernstein (ORCID: https://orcid.org/0000-0002-0100-1991)
Institutions
- Fukushima Medical University (JP)
- University of Wisconsin–Madison (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Barts Health NHS Trust (GB)
- Oxford Health NHS Foundation Trust (GB)
- National Jewish Health (US)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Bernstein Clinical Research Center (US)
- GlaxoSmithKline (United States) (US)
- Frauenklinik Heidelberg (DE)
- Oxford BioMedica (United Kingdom) (GB)
- State Key Laboratory of Respiratory Disease (CN)
- University of Cincinnati (US)
- Guangzhou Medical University (CN)
- University of Colorado Denver (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1056/nejmoa2406673
- Citations
- 94
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 30.70
Funders
- GlaxoSmithKline